Edwards Lifesciences Co. (NYSE:EW) Position Boosted by Jacobs & Co. CA

Jacobs & Co. CA raised its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 2.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 125,728 shares of the medical research company’s stock after buying an additional 2,828 shares during the quarter. Jacobs & Co. CA’s holdings in Edwards Lifesciences were worth $9,307,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Nordea Investment Management AB increased its position in Edwards Lifesciences by 34.6% in the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock worth $301,355,000 after buying an additional 1,043,484 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Edwards Lifesciences by 9.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 478,418 shares of the medical research company’s stock valued at $31,571,000 after purchasing an additional 40,348 shares in the last quarter. AIA Group Ltd raised its position in shares of Edwards Lifesciences by 91.7% during the 3rd quarter. AIA Group Ltd now owns 749,524 shares of the medical research company’s stock worth $49,461,000 after buying an additional 358,556 shares in the last quarter. RiverPark Advisors LLC lifted its position in Edwards Lifesciences by 58.1% in the third quarter. RiverPark Advisors LLC now owns 20,639 shares of the medical research company’s stock worth $1,362,000 after purchasing an additional 7,583 shares during the period. Finally, Banque Cantonale Vaudoise boosted its stake in Edwards Lifesciences by 46.9% during the 3rd quarter. Banque Cantonale Vaudoise now owns 81,111 shares of the medical research company’s stock valued at $5,353,000 after purchasing an additional 25,886 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total value of $347,550.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,262,521.36. This represents a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at approximately $1,717,841.12. The trade was a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 37,500 shares of company stock worth $2,508,350. 1.29% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research firms have recently commented on EW. Barclays boosted their price objective on Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a research note on Monday, December 2nd. Daiwa America lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. The Goldman Sachs Group boosted their target price on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, December 5th. Robert W. Baird decreased their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Finally, JPMorgan Chase & Co. increased their price objective on Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Sixteen investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Hold” and a consensus price target of $79.40.

Edwards Lifesciences Stock Down 0.4 %

NYSE EW traded down $0.28 on Friday, reaching $73.87. The stock had a trading volume of 1,637,123 shares, compared to its average volume of 3,622,711. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The business has a 50 day moving average price of $71.52 and a 200 day moving average price of $72.31. The company has a market capitalization of $43.57 billion, a price-to-earnings ratio of 10.66, a P/E/G ratio of 3.61 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same period in the previous year, the company earned $0.59 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 8.9% on a year-over-year basis. On average, analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.